Chimerix, Inc. (CMRX) Shares Surge After FDA Authorizes Potential Ebola Treatment

Shares of Chimerix, Inc. (CMRX) gained more than 8% to $32.37 in morning trading today after the company announced that the FDA approved the company’s drug brincidofovir for potential use in patients with Ebola. “Chimerix is committed to working with global health organizations and government agencies in the fight against the Ebola virus outbreak,” M. […] View the full post at: Chimerix, Inc. (CMRX) Shares Surge After FDA Authorizes Potential Ebola Treatment Related posts: The Potential for a Big Run in Agriculture Stocks Atlas Pipeline (APL) Shares Soar On Nat Gas Asset Sale